Bryan, Garnier & Co

Going public in 2014?

Bryan, Garnier & Co Annual IPO Conference
for European Growth Companies

Paris / May 13th, 8:30 - 12:30

Euronext Conference Center / 39-41, rue Cambon 75001 Paris

In partnership with

EnterNext Deloitte Deloitte

With the support of

France Biotech Afdel


Bryan, Garnier & Co held its annual IPO Conference in Paris on Tuesday, the 13th of May 2014, in partnership with EnterNext, Deloitte and ACTUS, and with the support of AFDEL and France Biotech.

In a buoyant IPO market which has not been experienced for half a decade, the opportunity of going public to raise growth capital or to access liquidity is being broadly evaluated by the management of growth companies and their shareholders.

The Conference has offered board members and senior executives of growth companies, private equity and venture capital professionals, a unique and timely opportunity to seize the current IPO market dynamics, and the key issues arising from the evaluation of an IPO track and its implementation to best take advantage of the current favorable IPO market.

Interview of Greg Revenu (in French), BFM Business TV


8:30 – 9:00

Registration and buffet breakfast

9:00 – 9:30

Primary capital markets environment : has the door opened in continental Europe ?

  • Eric Forest, EnterNext
  • Greg Revenu, Bryan, Garnier & Co

IPO market historical view and current outlook with an international perspective

9:30 – 10:00

The reason of going public : Financing growth, providing liquidity, is an IPO the answer?

  • Pierre Remy, Keensight Capital
  • Pierre-Olivier Goineau, Erytech Pharma

Opportunity of an IPO for the stakeholders, key expected benefits and perceived risks

10:00 – 10:30

Demystifying the IPO process and the constraints of being listed

  • Laurent Halfon, Deloitte
  • Laurent Bensaid, Hoche Société d’Avocats

Key considerations and challenges to address when considering an IPO

10:30 – 11:00

Coffee break

11:00 – 11:30

Key factors of a successful IPO

  • Pascal Mauberger, McPHy
  • Olivier Beaudouin, Bryan, Garnier & Co

Beyond the obvious, seizing the key criteria of a successful IPO

11.30 – 12:00

Remaining a successfull public company

  • Jérôme Fabreguettes-Leib, ACTUS
  • Jamal Labed, EasyVista
  • Eric Le Berrigaud, Bryan, Garnier & Co

Taking advantage of being listed and remaining a successful public company

12:00 – 12:30

The new frontier for publicly listed companies

  • Greg Revenu, Bryan, Garnier & Co

How does being listed impact further financing, acquisitions, liquidity and M&A strategies for the company and its shareholders


E. Forest

Eric Forest, CEO, EnterNext

Eric Forest joined Euronext Group as CEO of EnterNext in July 2013.
A graduate of Ecole Nationale Supérieure des Mines de Nancy, Eric began his career in 1986 and joined the ECM team of Société Générale in 1992. In 2003 he moved to Oddo Corporate Finance to head up their Equity Capital Markets business, where he oversaw IPOs, follow-on issues and secondary offerings. He was also in charge of Corporate Broking.
Over the last ten years, Eric has always worked in support of SMEs. He has participated actively in industry-level iscussions, helped numerous mid-sized companies gain access to the market through his ongoing responsibilities at Oddo, contributed to the creation of an analyst team dedicated to SMES and served as Chairman of ALIS, the association of NYSE Alternext’s Listing Sponsors. As head of EnterNext, Eric Forest is responsible for all activities and resources linked to SMEs within Euronext. He is also a member of the Issuers Consultative Commission of the Autorité des Marchés Financiers.

E. Berrigaud

Eric Le Berrigaud, Managing Partner Equities, Bryan, Garnier & Co

Eric Le Berrigaud, former Head of Research at Raymond James Euro Equities, joined Bryan, Garnier & Co as Managing Partner in 2011 responsible for Equities. He also heads up the Healthcare pole within the Research dept., which is a key franchise for the group. Eric began his career as a research analyst at Wargny in 1996 covering Biotech, Pharma, Oil stocks. From 1999 to 2004 he headed up the five-strong Healthcare team at Natexis Bleichroeder and moved to Raymond James Euro Equities in 2004, to be responsible for the Pharma sector and in particular, the coverage of large cap stocks (AstraZeneca, GSK, Novartis, Novo-Nordisk, Roche and Sanofi-Aventis). Aside from publishing research notes, marketing to institutional clients across France and abroad, and building relations with Corporate clients, Eric also undertook responsibilities for marketing events with corporate and doctors (including an Annual Vaccine Seminar since 2007 and regular field-trips to Basle and London). Eric is consistently classed amongst the best Pharma analysts in both external and internal rankings. Nominated Head of Research at Raymond James Euro Equities in 2006, Eric headed up a team of 10 and became a member of the Board of Raymond James European Securities in 2007. Eric has been a member of the SFAF since 2000 and is a graduate of the Ecole Supérieure de Commerce de Paris (ESCP) Majeure Finance – Promotion 1994.

G. Revenu

Grégoire Revenu, Managing Partner, Bryan, Garnier & Co

Greg is a co-founder and a Managing Partner of Bryan, Garnier & Co. He has been advising and financing European private and public growth companies for 20 years and has contributed to establish Bryan, Garnier & Co as one of the leading independent pan-European growth investment bank.  Conducting strategic acquisitions or trade sales, financing high growth companies through private and public capital markets has been Greg’s main focus for the past 20 years : In 1996, Greg was managing partner of one of the first European pre-IPO funds, and founded the first independent French VCT. He was instrumental in the launch of the European growth capital markets initiatives in the mid90s (Easdaq), and of Quartz Capital Partners, a London based investment bank focusing on technology and healthcare sectors, of which he served as a board member. Greg has conducted more than 80 transactions over the past 20 years, as an investor or an advisor, including private placements and PIPEs, buy-outs, sales and acquisitions, takeovers as well as public offerings both on the European and US markets. Greg holds a Post-Graduate Degree in Economics, a Master in Capital Markets Finance, as well as a BA in Business Law from the Paris University of Law and Economics.

J. Labed

Jamal Labed, Co-founder & COO, EasyVista

Jamal Labed has more than 25 years of entrepreneurial experience in the Software industry. He is co-founder and COO of the EasyVista group, an ITSM solution editor with offices in 8 European countries as well in the United States and Canada and which is listed on Euronext since 2005. Jamal is particularly in charge of driving the North American development strategy at EasyVista. In addition to his position at EasyVista, Jamal Labed is also the President of the AFDEL (French association of software editors and Internet solutions), a professional organization representing more than 350 ISV. Jamal Labed has been awarded “Chevalier” of the French National Order of the Legion of Honour.

J. Fabreguettes-Leib

Jérôme Fabreguettes-Leib, Deputy CEO, ACTUS finance & communication

As Deputy CEO at ACTUS since 2012, Jérôme Fabreguettes-Leib places his expertise and experience in both finance & communication at the disposal of business leaders and executives across a broad spectrum of industries and fields.
In 2000, Jérôme joined the editorial team of Investir, France's leading weekly investment magazine, where he spent over 7 years analyzing and providing recommendations on listed companies from the Automobile, Media and Consumer Electronics sectors. At the start of 2008, Jérôme joined Kaparca Finance just a few months prior to its merger with ACTUS which cemented the new entity's position as the leading financial communications agency in France. As Consultant Director then Deputy CEO, Jérôme has directly managed primary (IPOs and IBOs) and secondary (capital increases, tender offers, etc.) operations and works in a permanent advisory capacity alongside the management teams of Euronext listed companies.
Jérôme Fabreguettes-Leib holds a Master's Degree in Economics from Paris-Dauphine University.

L. Bensaid

Laurent Bensaid, Partner, Hoche Société d’Avocats

Laurent Bensaid has extensive experience in mergers and acquisitions and capital market transactions. He advises domestic and foreign companies, investment funds and investment banks on a broad range of transactions, including acquisitions of both listed and private companies, IPOs and public offers. Prior to joining Hoche, highlights of Laurent Bensaid’s M&A practice have included the following transactions: He advised EDF in connection with the acquisition of strategic assets in Belgium (2008 – 2009) and Business Objects in connection with the tender offer launched by SAP (2008), the transfer of assets to ataven (2008) and the acquisition of the Cartesis Group (2007). Laurent advised Spie Batignolles in its MBO (2008), He also advised France Télécom in connection with the sale of its majority interest in Pages Jaunes (2006) and in its acquisition of a minority interest in Equant (2005). He was also involved in CFF Recycling’s acquisition of interest in Penauille Polyservices (2005), in Schiphol’s acquisition of a minority stake of Aéroport de Paris (2008), and in Malakoff-Médéric’s acquisition of a minority stake in Korian (2008). He also advised on the restructuring of Duran’s capital (2009). Concerning capital markets, Laurent’s prior experience has included the following transactions:
he advised EDF in connection with the initial public offering by EDF Energies Nouvelles (2006); and the underwriters in EDF’s €7.5 billion privatization, considered as one of the largest IPO ever in France (2005). Laurent holds a Master in business law, an IDA diploma and a Postgraduate degree in business law from Panthéon Assas and an MBA from Paris Dauphine. He also holds an LL.M from Columbia Law School.

L. Halfon

Laurent Halfon, Partner, Deloitte

Laurent, an Authorized Public Accountant, is a Partner at Deloitte Paris, France. He is the leader of the TMT practice in France. He has served growth companies for 15 years and has gained a considerable experience in the management and coordination of international as well as national audit assignments. Laurent is recognized as an experienced practitioner in IPO especially in the ​​Life Sciences and IT area. Partner in charge of Deloitte Technology Fast50 in France, which provides a ranking of the fastest growing TMT companies, he is often interviewed in the media (Challenges, Le Monde, France Info ...).He is a speaker on topics such as fundraising and IPO and is a teacher in Paris Dauphine.

O. Baudoin

Olivier Beaudouin, Partner, Technology & Cleantech,
Bryan Garnier & Co

Olivier Beaudouin has 19 years of experience in Investment Banking, of which 14 in the Technology sector. He joined Bryan, Garnier & Co in 2007 to strengthen the bank’s Technology practice, subsequently heading-up the Cleantech development effort. Prior to joining BG, Olivier led the hardware technology effort within SG’s M&A TMT Group in Paris after spending 4 years covering communications equipment and semiconductors at Corporate Finance outfit Cowen & Co in London. He started his carrier within SG in New York and Sao Paulo where he provided capital raising and advisory services to Latin American companies. Olivier has been involved in a broad scope of Corporate Finance (ECM, M&A and Private Placement) transactions in Technology and Cleantech. On the Technology front he has managed assignments in communications Infrastructure, software, semiconductors and electronics, advising listed multinationals such as Alcatel, ST Micro, Gemalto, Thales, Thomson, Orange or CapGemini, as well as emerging technology leaders such as Metrologic, Infovista, Metrologic, Orolia, Parrot, Inmarsat or Cambridge Silicon Radio.

P. Mauberger

Pascal Mauberger, CEO, McPhy Energy

Pascal has gained over 25 years of experience in high-tech industries. From 1993 to 2001, he headed the reorganization of Air Liquide’s engineering division as its Operational Director. He then became Vice President of Vivendi Water Systems, a position he held between 2001 and 2003. Before joining McPhy, he was COO of Soitec (a leading Silicon-On-Insulator company) from 2003 until 2008. Under his management, the company successfully grew from €80M in revenue in March 2004 to €370M in March 2007. Pascal is a graduate from top-tier engineering schools École Polytechnique and ENSPM and holds a Young Manager Program degree from INSEAD business school.

P. Remy

Pierre Remy, Founding Partner, Keensight Capital

Pierre is a Founding Partner of Keensight Capital and has over 16 years of successful private equity investment experience. During his investing experience, he invested in several companies which subsequently went public on European or US markets such as Vist@print, Swan, Danionics, LDR… Prior to founding Keensight, he spent 10 years with the Rothschild group as a Managing Partner of R Capital Management, the investment arm of the Rothschild Group dedicated to growth companies. R Capital Management became Keensight after its Managing Partners acquired Rothschild Group’s stake in the company. He started his investment career working for Natixis, one of the private equity pioneers in Europe. Before this, he was a Senior Manager with Ernst & Young in the firm's strategy and organizational practice. He started his career as an engineer in the Automotive and Aerospace industries. Pierre is a graduate of Sciences Po Paris and holds an Engineering degree from ENSAM, Paris. Today, Pierre serves on the board of SFA Romani, Menix and LDR.

P-0. Goineau

Pierre-Olivier Goineau, Co-founder, VP and COO, Erytech Pharma, Chairman of France Biotech

Co-Founder and Vice-President, Chief Operating Officer of ERYTECH Pharma. Before co-founding the company, Pierre-Olivier was Senior Consultant in Strategy and Development at KPMG in Lyons, France, where he was in charge of the Health division. Pierre-Olivier is Vice-President of the Board of Directors of “France Biotech”, the French association for biotechnology. Pierre Olivier has a DEA (post-graduate degree) in Management Science and a Master’s degree in Pharmaceutical Industry Management from the IAE (School of Business Management) in Lyons, France. Pierre-Olivier is the President of France Biotech since February 2014.

About Bryan, Garnier & Co

Bryan, Garnier & Co is an international growth focused independent investment bank with operations in London, Paris, Geneva, New York and New Delhi. The firm employs 120 professionals and provides investment management, equity research, sales & trading and investment banking (private and public capital raising and M&A) services to growth companies and their investors, with a focus on the TMT, Healthcare, Renewable Energies & Environment, Specialty Retail and Business Services industry sectors. Bryan, Garnier & Co regularly keeps top spot in the European M&A and Equity Capital Markets league tables in Technology, Media Telecom and Healthcare sectors. The firm benefits from a strong recognition of its pan-European equity research activity which was awarded Most Productive European Broker for 2013 by Financial Times / Starmine. In April 2014, Bryan, Garnier & Co investment banking activities were awarded best investment bank of the year in TMT and Healthcare by Leaders League.

Recently, Bryan, Garnier & Co led the largest healthcare IPO on NYSE Euronext in H1 2013, was joint lead manager and bookrunner of LDR Nasdaq IPO in October 2013, acted as sole manager of Transgene 65m€ PIPE-, led one of the largest European private placement for Merieux Nutrisciences, and acted as lead manager of Erytech, Genomic Vision and McPhy Energy IPOs on NYSE Euronext.

Bryan, Garnier & Co is a fully registered broker dealer authorized by the FCA in Europe and by the FINRA in the USA, is a member of the London Stock Exchange, a member of NYSE Euronext and a listing sponsor on Alternext. In April 2014, the firm announced a strategic alliance with City stockbroker Westhouse Securities to increase its presence on the UK domestic small cap market segment.